Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Personalized neo-antigen-targeted immunotherapy development for advanced colorectal cancer
NL-OMON42438Not yet recruiting
- Sponsor
- Leiden University Medical Center
- Start
- Oct 2015
- Countries
- 1
01
Overview
Open-label, single-arm trial in colorectal cancer (CRC), sponsored by Leiden University Medical Center. Primary endpoints: Percentage of advanced colorectal cancer patients with neo-antigen-reactive autologous T cells and Estimated proportion of patients who may benefit from neo-antigen-targeted therapies. Planned start Oct 2015; status: not yet recruiting.
02
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NL-OMON42438.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON42438.